PFE Jan 2025 42.500 call
| Previous Close | 0.1000 |
| Open | 0.1100 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 42.50 |
| Expire Date | 2025-01-17 |
| Day's Range | 0.1000 - 0.1100 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
BloombergModerna’s mRNA Dreams Meet Reality With First Post-Covid Shot
(Bloomberg) -- Moderna Inc.’s pioneering Covid shot turned the company into a nearly $200 billion biotech giant and a public health hero. Its second vaccine, meant to prevent a common respiratory virus, is calling into question the premise on which the company has staked its entire business. Most Read from BloombergMicrosoft’s Xbox Is Planning More Cuts After Studio ClosingsAmericans Are Racking Up ‘Phantom Debt’ That Wall Street Can’t TrackStormy Daniels Will Return to Court in Test of Trump’s
Investor's Business DailyPfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Pfizer stock ran up to its 50-day line after the company reported better-than-expected sales and profit. Is PFE stock a buy?
Insider MonkeyOPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript
OPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript May 7, 2024 OPKO Health, Inc. misses on earnings expectations. Reported EPS is $-0.11577 EPS, expectations were $-0.09. OPKO Health, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and […]
